Published July 31, 2024 | Version https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue7,Article275.pdf
Journal article Open

To Study Thyroid Profile as Risk Factor in Non-Alcoholic Fatty Liver Disease (NAFLD) Patients

Authors/Creators

  • 1. Professor and Head of the Department of General Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, India
  • 2. Resident Doctor, Department of General Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, India
  • 3. Professor and Unit Head of Department of General Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, India
  • 4. Professor, Department of General Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, India
  • 5. Associate Professor, Department of General Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, India
  • 6. Assistant Professor, Department of General Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, India
  • 7. Senior Resident, Department of General Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, India
  • 8. Resident doctor, Department of General Medicine, Mahatma Gandhi Medical College and Hospital, Jaipur, India

Description

Aims: To study the prevalence of thyroid dysfunction as risk factor associated with severity of NAFLD.
Objectives: Primary Objective: To assess prevalence of hypothyroidism in NAFLD patients. Secondary objective: To assess association of hypothyroidism as risk factor in NAFLD patients. Methodology: Present study was an observational prospective study between January 2023 to June 2024 in patients between age group 25-65 years attend OPD/IPD services at Department of Medicine, Mahatma Gandhi Hospital, Jaipur. Results: The study observed significant associations between thyroid function parameters and non-alcoholic fatty liver disease (NAFLD), particularly with thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), and free thyroxine (fT4) levels. Lower levels of fT3 and fT4 were found to be associated with increased odds of NAFLD (p < 0.001). Thyroid hormones play a crucial role in regulating hepatic lipid metabolism. They modulate the expression of genes involved in lipogenesis, β-oxidation, and cholesterol metabolism in the liver. Reduced thyroid hormone levels, as observed in hypothyroidism or subclinical hypothyroidism, can lead to impaired lipid metabolism, promoting hepatic steatosis. Conclusion: Thyroid hormones influence insulin sensitivity and glucose metabolism, with hypothyroidism often associated with insulin resistance and dysglycemia. Insulin resistance is a key pathogenic factor in NAFLD development, contributing to excessive hepatic lipid accumulation. Thus, alterations in thyroid function may exacerbate insulin resistance and further predispose individuals to NAFLD (36). Thyroid hormones exert anti-inflammatory and antifibrotic effects in various tissues, including the liver. Hypothyroidism is associated with increased pro-inflammatory cytokine levels and oxidative stress, which can promote hepatic inflammation and fibrogenesis, contributing to NAFLD progression.

Abstract (English)

Aims: To study the prevalence of thyroid dysfunction as risk factor associated with severity of NAFLD.
Objectives: Primary Objective: To assess prevalence of hypothyroidism in NAFLD patients. Secondary objective: To assess association of hypothyroidism as risk factor in NAFLD patients. Methodology: Present study was an observational prospective study between January 2023 to June 2024 in patients between age group 25-65 years attend OPD/IPD services at Department of Medicine, Mahatma Gandhi Hospital, Jaipur. Results: The study observed significant associations between thyroid function parameters and non-alcoholic fatty liver disease (NAFLD), particularly with thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), and free thyroxine (fT4) levels. Lower levels of fT3 and fT4 were found to be associated with increased odds of NAFLD (p < 0.001). Thyroid hormones play a crucial role in regulating hepatic lipid metabolism. They modulate the expression of genes involved in lipogenesis, β-oxidation, and cholesterol metabolism in the liver. Reduced thyroid hormone levels, as observed in hypothyroidism or subclinical hypothyroidism, can lead to impaired lipid metabolism, promoting hepatic steatosis. Conclusion: Thyroid hormones influence insulin sensitivity and glucose metabolism, with hypothyroidism often associated with insulin resistance and dysglycemia. Insulin resistance is a key pathogenic factor in NAFLD development, contributing to excessive hepatic lipid accumulation. Thus, alterations in thyroid function may exacerbate insulin resistance and further predispose individuals to NAFLD (36). Thyroid hormones exert anti-inflammatory and antifibrotic effects in various tissues, including the liver. Hypothyroidism is associated with increased pro-inflammatory cytokine levels and oxidative stress, which can promote hepatic inflammation and fibrogenesis, contributing to NAFLD progression.

Files

IJPCR,Vol16,Issue7,Article275.pdf

Files (581.8 kB)

Name Size Download all
md5:9d7fabfffac387f5960e1ded738c17ae
581.8 kB Preview Download

Additional details

Identifiers

URL
https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue7,Article275.pdf

Dates

Accepted
2024-06-26

Software

Repository URL
https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue7,Article275.pdf
Development Status
Active

References

  • 1. Neuschwander-Tetri, B.A.; Caldwell, S.H. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology 2003, 37, 1202–1219.2. LaBrecque D.R., Abbas Z., Anania F., Ferenci P., Khan A.G., Goh K.L. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2012; 48:467–473. 3. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 2010; 53:372–384. 4. Sookoian S., Pirola C.J. Systematic review with meta-analysis: Risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment. Pharmacol. Ther. 2017; 46:85–95. 5. Marchisello S., Di Pino A., Scicali R., Urbano F., Piro S., Purrello F., Rabuazzo A.M. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int. J. Mol. Sci. 2019; 20:1948. 6. Fan J.G., Saibara T., Chitturi S., Kim B.I., Sung J.J.Y., Chutaputti A. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J. Gastroenterol. Hepatol. 2007; 22:794–800. 7. Miyake T., Kumagi T., Furukawa S., Tokumoto Y., Hirooka M., Abe M., Hiasa Y., Matsuura B., Onji M. Non-alcoholic fatty liver disease: Factors associated with its presence and onset. J. Gastroenterol. Hepatol. 2013; 28:71–78. 8. Wu S.J., Zhu G.Q., Ye B.Z., Kong F.Q., Zheng Z.X., Zou H., Shi K.Q., Lin L., Braddock M., Huang W.J., et al. Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults. Medicine. 2015; 94:1–10. 9. Michalaki MA, Vagenakis AG, Leonardou AS, Argentou MN, Habeos IG, Makri MG, Psyrogiannis AI, Kalfarentzos FE, Kyriazopoulou VE. Thyroid function in humans with morbid obesity. Thyroid. 2006; 16:73–78. 10. Raftopoulos Y, Gagné DJ, Papasavas P, Hayetian F, Maurer J, Bononi P, Caushaj PF. Improvement of hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2004; 14:509–513. 11. Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, Asvold BO, Iervasi G, Imaizumi M, Collet TH, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010; 304:1365– 1374. 12. Pucci E, Chiovato L, Pinchera A. Thyroid and lipid metabolism. Int J Obes Relat Metab Disord. 2000; 24 Suppl 2:S109–S112. 13. Yilmaz Y. NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression? Semin Liver Dis. 2012; 32:14–21. 14. Collantes RS, Ong JP, Younossi ZM. The metabolic syndrome and nonalcoholic fatty liver disease. Panminerva Med. 2006; 48:41–48. 15. Pearce EN. Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes. 2012; 19:408– 413. 16. Pacifico L, Anania C, Ferraro F, Andreoli GM, Chiesa C. Thyroid function in childhood obesity and metabolic comorbidity. Clin Chim Acta. 2012; 413:396–405. 17. Waring AC, Rodondi N, Harrison S, Kanaya AM, Simonsick EM, Miljkovic I, Satterfield S, Newman AB, Bauer DC. Thyroid function and prevalent and incident metabolic syndrome in older adults: the Health, Ageing and Body Composition Study. Clin Endocrinol (Oxf) 2012; 76:911–918. 18. Kowalska I, Borawski J, Nikołajuk A, Budlewski T, Otziomek E, Górska M, Strączkowski M. Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy. Endocrine. 2011; 40:95– 101. 19. Smithson MJ. Screening for thyroid dysfunction in a community population of diabetic patients. Diabet Med. 1998; 15:148–150. 20. Díez JJ, Iglesias P. Subclinical hyperthyroidism in patients with type 2 diabetes. Endocrine. 2012; 42:157–163. 21. Yamada, T.; Fukatsu, M.; Suzuki, S.; Wada, T.; Joh, T. Elevated serum uric acid predicts impaired fasting glucose and type 2 diabetes only among Japanese women undergoing health checkups. Diabetes Metab. 2011, 37, 252–258. 22. Corry, D.B.; Eslami, P.; Yamamoto, K.; Nyby, M.D.; Makino, H.; Tuck, M.L. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J. Hypertens. 2008, 26, 269– 275. 23. Kang, D.H.; Park, S.K.; Lee, I.K.; Johnson, R.J. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. J. Am. Soc. Nephrol. 2005, 16, 3553–3562. 24. Ginsberg, M.H.; Kozin, F.; O'malley, M.; McCarty, D.J. Release of platelet constituents by monosodium urate crystals. J. Clin. Investig. 1977, 60, 999–1007. 25. Sertoglu, E.; Ercin, C.N.; Celebi, G.; Gurel, H.; Kayadibi, H.; Genc, H.; Kara, M.; Dogru, T. The relationship of serum uric acid with nonalcoholic fatty liver disease. Clin. Biochem. 2014, 47, 383–388. 26. Sesti, G.; Fiorentino, T.V.; Arturi, F.; Perticone, M.; Sciacqua, A.; Perticone, F. Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. PLoS ONE 2014, 9, e88569.27. Nakatsu, Y.; Seno, Y.; Kushiyama, A.; Sakoda, H.; Fujishiro, M.; Katasako, A.; Mori, K.; Matsunaga, Y.; Fukushima, T.; Kanaoka, R.; et al. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am. J. Physiol. Gastrointest. Liver Physiol. 2015, 309, 42–51. 28. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37:917–23. 29. Pirgon O, Bilgin H, Tolu I, et al. Correlation of insulin sensitivity with bone mineral status in obese adolescents with nonalcoholic fatty liver disease. Clin Endocrinol 2011; 75:189–95. 30. Whooley MA, Kip KE, Cauley JA, et al. Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999; 159:484– 90. 31. Younossi Z., Tacke F., Arrese M., Sharma B.C., Mostafa I., Bugianesi E., Wong V.W., Yilmaz Y., George J., Fan J., et al. Global Perspectives on Non-alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019; 69:2672–2682. 32. Younossi Z., Anstee Q.M., Marietti M., Hardy T., Henry L., Eslam M., George J., Bugianesi E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018; 15:11–20. 33. Pagadala MR, Zein CO, Dasarathy S, Yerian LM, Lopez R, McCullough AJ. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci. 2012 Feb; 57(2):528-34. 34. Zhang J., Sun H., Chen L., Zheng J., Hu X., Wang S., Chen T. Relationship between serum TSH level with obesity and NAFLD in euthyroid subjects. J. Huazhong Univ. Sci. Technol. Med. Sci. 2012; 32:47–52. 35. Coppola M., Cioffi F., Moreno M., Goglia F., Silvestri E. 3,5-diiodo-L-thyronine: A Possible Pharmacological Agent? Curr. Drug Deliv. 2016; 13:330–338. 36. 36. Maratou E, Hadjidakis DJ, Kollias A, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol. 2009; 160(5):785-790.